Gastroparesis

1. Overview
2. Causes and Risk Factors
3. Pathophysiology: Interstitial Cells of Cajal and Vagal Neuropathy
4. Symptoms and Complications
5. Diagnosis: Gastric Emptying Scintigraphy
6. Dietary Management
7. Medications and Prokinetics
8. Procedures and Advanced Therapies
9. Research Papers
10. Connections
11. Featured Videos

Overview

Gastroparesis is a chronic disorder of gastric motility defined by delayed emptying of the stomach in the absence of mechanical obstruction. The stomach fails to propel its contents into the small intestine at a normal rate, leading to prolonged food retention and a characteristic cluster of upper gastrointestinal symptoms.

The term comes from the Greek gastro (stomach) and paresis (partial paralysis). Unlike pyloric stenosis or gastric outlet obstruction — where a physical blockage prevents emptying — gastroparesis is a functional disorder. Imaging and endoscopy reveal no anatomic obstruction; the problem lies entirely in the motor machinery of the stomach itself.

Gastroparesis affects an estimated 1.8–4% of the US population, with women affected two to four times more frequently than men. The condition spans a wide severity spectrum: some patients manage with dietary adjustments alone, while others experience relentless vomiting, profound malnutrition, and frequent hospitalization. Glycemic control in diabetic patients is particularly difficult when gastroparesis makes food absorption unpredictable.

↑ Back to Table of Contents

Causes and Risk Factors

Gastroparesis is classified by etiology. Identifying the underlying cause matters both for prognosis and treatment strategy.

Diabetic Gastroparesis (most common identifiable cause)

• Results from autonomic neuropathy — a long-term complication of poorly controlled diabetes mellitus
• Prevalence approximately 30–50% in patients with longstanding type 1 or type 2 diabetes
• Vagal nerve damage impairs the coordinated gastric motor response to a meal
• Hyperglycemia itself acutely inhibits gastric motility — glucose >144 mg/dL slows emptying even in people without established neuropathy
• Duration of diabetes and degree of glycemic control are the main risk determinants

Idiopathic Gastroparesis (second most common)

• No identifiable systemic cause; often follows a viral illness (post-infectious gastroparesis)
• Affects women far more than men; typical onset in younger adults
• Some cases spontaneously improve over months to years; others are chronic and refractory
• Suspected viral triggers include cytomegalovirus, Epstein-Barr virus, norovirus, and enteric adenoviruses

Post-Surgical Gastroparesis

• Vagotomy (historically performed for peptic ulcer disease) — directly disrupts vagal innervation of the stomach
• Nissen fundoplication — anti-reflux surgery can inadvertently injure vagal branches
• Bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass)
• Partial gastrectomy with removal of the pylorus (Billroth procedures)
• Esophagectomy with gastric pull-up reconstruction

Neurological and Systemic Causes

• Parkinson's disease — alpha-synuclein deposition in the enteric nervous system; GI symptoms often precede motor symptoms by years
• Multiple sclerosis
• Amyloidosis — infiltrates the enteric nervous system
• Scleroderma (systemic sclerosis) — smooth muscle fibrosis throughout the GI tract
• Ehlers-Danlos syndrome and other connective tissue disorders

Medication-Induced

• Opioids (highly prevalent cause — all opioids slow GI motility via enteric mu-opioid receptors)
• Anticholinergics (tricyclic antidepressants, some antihistamines, bladder medications)
• GLP-1 receptor agonists (semaglutide, liraglutide) — slowed gastric emptying is a therapeutic mechanism but can become symptomatic
• Calcium channel blockers, dopamine agonists

↑ Back to Table of Contents

Pathophysiology: Interstitial Cells of Cajal and Vagal Neuropathy

Normal gastric emptying requires the coordinated interaction of three systems: the enteric nervous system, gastric smooth muscle, and the interstitial cells of Cajal (ICC). Gastroparesis results from dysfunction of one or more of these components.

Interstitial Cells of Cajal (ICC)

• ICC are the pacemaker cells of the stomach — they generate the electrical slow wave (3 cycles/minute in humans) that coordinates peristalsis
• Located at the myenteric plexus and within the circular and longitudinal muscle layers
• Full-thickness gastric biopsies from gastroparesis patients consistently show reduced ICC density (loss of 40–80% versus controls in severe cases)
• ICC loss disrupts the electrical propagation needed for organized antral contractions
• Oxidative stress, CD206+ macrophage deficiency, and reduced heme oxygenase-1 (HO-1) have been identified as ICC-damaging mechanisms in diabetic gastroparesis

Vagal Neuropathy

• The vagus nerve coordinates the cephalic phase of digestion and stimulates antral contractions in response to food
• Diabetic autonomic neuropathy damages vagal efferents, reducing acetylcholine release onto gastric smooth muscle
• Vagal afferents also transmit satiety signals — their impairment disrupts normal feedback between stomach distension and appetite regulation

Smooth Muscle Dysfunction

• In scleroderma and some idiopathic cases, the smooth muscle itself is the primary problem — fibrosis replaces contractile tissue
• Nitric oxide synthase (NOS) — the inhibitory neurotransmitter system controlling pyloric relaxation — is upregulated in diabetic gastroparesis, causing pyloric spasm and functional outflow resistance
• This pyloric hypercontractility is the mechanistic basis for pyloric interventions (botulinum toxin, G-POEM, pyloroplasty)

Antroduodenal Dyscoordination

• Normal emptying requires synchronized antral contractions, pyloric relaxation, and duodenal receptivity
• In gastroparesis, antral hypomotility and pyloric dysfunction occur simultaneously — meal contents are not propelled through the pylorus efficiently
• Gastric fundus distension (normally mediates accommodation) may also be impaired, worsening early satiety and postprandial pain

↑ Back to Table of Contents

Symptoms and Complications

Cardinal Symptoms

• Nausea — the most prominent and consistent symptom; present in over 90% of patients; often chronic and debilitating
• Vomiting — characteristically contains undigested or partially digested food consumed more than one hour earlier (distinguishes gastroparesis from mechanical obstruction or pyloric stenosis)
• Early satiety — feeling full after only a few bites; a direct consequence of impaired gastric accommodation and slow emptying
• Postprandial fullness — prolonged sense of food "sitting" in the stomach after eating
• Upper abdominal pain and bloating — variable in character; worse after meals; distension from retained gastric contents

Severity Assessment

The Gastroparesis Cardinal Symptom Index (GCSI) is the validated patient-reported outcome measure — scores nausea, vomiting, early satiety, fullness, bloating, and upper abdominal pain on 0–5 scales. GCSI scores track disease severity and treatment response in clinical trials.

Complications

• Malnutrition — chronic inadequate caloric and nutrient intake; weight loss is common and can be severe in refractory gastroparesis
• Dehydration — persistent vomiting depletes fluid and electrolytes; hypokalemia, hyponatremia, and metabolic alkalosis
• Bezoar formation — retained undigested material (particularly vegetable fiber) consolidates into a solid mass; can cause gastric outlet obstruction and ulceration
• Erratic glycemic control in diabetes — unpredictable food absorption timing makes insulin dosing unreliable; hypoglycemia after insulin injection (food not yet absorbed) and postprandial hyperglycemia alternate unpredictably
• Esophageal complications — recurrent vomiting causes reflux, esophagitis, and Mallory-Weiss tears
• Hospitalization burden — severe gastroparesis requires repeated admissions for IV hydration, antiemetics, and nutritional support

↑ Back to Table of Contents

Diagnosis: Gastric Emptying Scintigraphy

The diagnosis of gastroparesis requires documenting objectively delayed gastric emptying after mechanical obstruction has been excluded.

Gastric Emptying Scintigraphy (GES) — Gold Standard

• The 4-hour standardized solid-phase protocol is required for accurate diagnosis — 2-hour protocols have poor sensitivity for mild-to-moderate gastroparesis
• Meal: 99mTc-sulfur colloid egg meal (120 kcal: 2 scrambled eggs + toast + jam + water)
• Images acquired at 0, 1, 2, and 4 hours; normal = <10% retention at 4 hours
• Severity thresholds: 10–35% retained = mild delay; 35–60% = moderate; >60% = severe gastroparesis
• Patient preparation is critical: fast ≥4 hours before the test; hold opioids, anticholinergics, and prokinetics 48–72 hours prior; fasting blood glucose must be normal (hyperglycemia >144 mg/dL independently delays emptying and will produce false-positive results)
• Medications affecting gastric motility must be documented and accounted for in interpretation

Wireless Motility Capsule (SmartPill)

• Ingestible capsule measuring pH, pressure, and temperature throughout the GI tract
• Provides gastric emptying time, small bowel transit time, and colonic transit time in a single test
• Detects gastroparesis when gastric emptying time exceeds 5 hours
• FDA-cleared; useful in patients who cannot undergo nuclear medicine or when whole-gut motility assessment is needed

13C-Octanoate Breath Test

• Non-radioactive, non-invasive alternative to scintigraphy
• 13C-labeled octanoic acid is metabolized and detected as 13CO2 in exhaled breath
• Rate of 13CO2 appearance correlates with gastric emptying rate
• Not available at all centers; good correlation with scintigraphy in validation studies

Mandatory Prior Workup

• Upper endoscopy (EGD) — mandatory before confirming gastroparesis; excludes peptic ulcer, gastric outlet obstruction, pyloric stenosis, malignancy, and retained food from prior obstruction
• CT scan — excludes extrinsic compression from adjacent structures or masses
• Laboratory workup — HbA1c, thyroid function (hypothyroidism slows motility), electrolytes, complete metabolic panel
• The diagnosis of gastroparesis is established only after endoscopic and imaging exclusion of mechanical causes

↑ Back to Table of Contents

Dietary Management

Dietary modification is the foundation of gastroparesis management and should be the first intervention for all patients regardless of severity.

Meal Structure

• Small, frequent meals — 6 small meals per day rather than 3 large ones; smaller volumes empty faster and reduce postprandial symptoms
• Eat slowly; chew food thoroughly; remain upright for at least 2 hours after eating
• Liquids empty faster than solids — liquid nutrition supplements (Ensure, Boost, Carnation Breakfast Essentials) may be better tolerated during flares
• Avoid lying down after meals; elevate the head of bed if nocturnal symptoms are prominent

Macronutrient Modifications

• Low fat diet (<40g/day) — dietary fat slows gastric emptying; reducing fat accelerates it; aim for <40g total fat/day
• Low insoluble fiber — insoluble fiber (raw vegetables, seeds, nuts, fibrous peels) resists digestion and contributes to bezoar formation; limit or avoid
• Soluble fiber (oatmeal, soft cooked vegetables, applesauce) is generally better tolerated
• Avoid carbonated beverages — excess gas worsens bloating and distension

Food Texture

• Progress from a liquid diet during acute flares → soft/pureed foods → soft solids as tolerated
• Well-cooked, tender meats (ground, shredded); soft cooked vegetables; mashed potatoes; soft cooked grains
• Avoid tough raw vegetables, large meat portions, high-fat foods (fried foods, cream sauces, fatty meats)
• Avoid high-fiber foods that risk bezoar formation: citrus pith, apple skins, coconut, dried fruits, uncooked brassica vegetables

Nutritional Support for Severe Cases

• When oral intake cannot maintain adequate nutrition: liquid nutritional supplements provide concentrated calories in easily emptied form
• Jejunal tube feeding (nasojejunal or jejunostomy) bypasses the stomach entirely — an effective bridge for patients who cannot maintain nutrition orally; preferred over gastric tube feeding in gastroparesis
• Parenteral nutrition reserved for patients who cannot tolerate any enteral route
• Nutritional assessment by a registered dietitian experienced in gastroparesis is strongly recommended for moderate-severe cases

↑ Back to Table of Contents

Medications and Prokinetics

Pharmacologic therapy targets two goals: accelerating gastric emptying (prokinetics) and controlling symptoms (antiemetics). No currently available medication reliably achieves both goals without significant side effects.

Metoclopramide — Only FDA-Approved Drug for Gastroparesis in the United States

• Mechanism: dopamine D2 receptor antagonist (blocks inhibitory dopamine signaling in the enteric nervous system) + 5-HT4 receptor agonist (stimulates acetylcholine release, promotes antral contractions)
• Dose: 10–15 mg orally or IV four times daily, 30 minutes before meals and at bedtime
• BLACK BOX WARNING — Tardive Dyskinesia (TD): involuntary repetitive movements (facial grimacing, tongue protrusion, lip smacking) that may be irreversible even after discontinuation; risk increases with cumulative dose and duration; limit use to ≤12 weeks and lowest effective dose
• Additional CNS side effects: drowsiness, restlessness, akathisia, acute dystonic reactions
• Available as oral tablet, oral solution, and IV formulation; liquid form may be better absorbed in gastroparesis

Domperidone

• Peripheral D2 antagonist — does not cross the blood-brain barrier in significant amounts, so CNS and extrapyramidal side effects are much less common than metoclopramide
• Dose: 10–20 mg three to four times daily before meals
• Not FDA-approved in the United States — available via FDA Investigational New Drug (IND) expanded access program; widely used in Canada, Europe, and elsewhere
• Cardiac risk: prolongs QTc interval — baseline ECG required; avoid with other QT-prolonging drugs and in patients with cardiac disease

Erythromycin

• Motilin receptor agonist — motilin is the hormone that triggers phase III of the migrating motor complex (gastric "housekeeping" contractions between meals)
• Most potent prokinetic available short-term; IV erythromycin is used acutely hospitalized patients
• Oral dose: 125–250 mg three times daily before meals
• Tachyphylaxis — rapid loss of efficacy with regular use limits long-term value; most useful as a short-term intervention or intermittently
• Drug interactions: inhibits CYP3A4 (numerous interactions); QT prolongation risk

Prucalopride

• Selective 5-HT4 agonist; FDA-approved for chronic idiopathic constipation (not specifically for gastroparesis)
• Off-label use in gastroparesis; favorable safety profile compared to older 5-HT4 agonists (no cardiac QT effects)
• Dose: 1–2 mg daily
• Growing evidence base for accelerating gastric emptying; may become a preferred agent as data mature

Symptom Control — Antiemetics

• Ondansetron (5-HT3 antagonist): well-tolerated first-line antiemetic; does not accelerate emptying but effectively controls nausea and vomiting; 4–8 mg orally or ODT (orally disintegrating tablet — useful when vomiting prevents swallowing)
• Promethazine: phenothiazine antiemetic; useful for refractory nausea; sedating; avoid long-term use (TD risk, same class concern as metoclopramide)
• Tricyclic antidepressants (TCAs) at low dose (nortriptyline 10–75 mg): centrally modulate nausea perception; nortriptyline preferred over amitriptyline (less anticholinergic effect on motility)
• Mirtazapine: 5-HT3 antagonist + appetite stimulant; may reduce nausea and promote weight gain; off-label but used clinically

↑ Back to Table of Contents

Procedures and Advanced Therapies

Gastric Electrical Stimulation (GES) — Enterra Device

• An implantable neurostimulator (similar in concept to a cardiac pacemaker) delivers high-frequency, low-energy electrical pulses to the gastric wall via two electrodes implanted in the muscle layer
• FDA humanitarian device exemption (HDE) — approved for patients with refractory nausea and vomiting from diabetic or idiopathic gastroparesis that has not responded to medications
• Mechanism is incompletely understood — GES does not consistently accelerate gastric emptying rate on scintigraphy, but it significantly reduces nausea and vomiting, hospitalizations, and improves quality of life in diabetic and idiopathic patients
• Responders: diabetic gastroparesis responds better than idiopathic; nausea/vomiting responds better than pain-predominant symptoms
• Device is surgically implanted (laparoscopic procedure) into a subcutaneous pocket in the abdominal wall; requires periodic battery replacement

Intrapyloric Botulinum Toxin Injection

• Endoscopic injection of botulinum toxin A into the pyloric sphincter — rationale: temporarily paralyze pyloric spasm, reduce outflow resistance
• Two randomized placebo-controlled trials (including PMID 16000734) showed no significant benefit over placebo for gastric emptying rate or symptom scores in unselected gastroparesis patients
• Some clinicians use it selectively when high-resolution antroduodenal manometry demonstrates isolated pyloric dysfunction; evidence remains insufficient for routine recommendation
• Effects are temporary (3–4 months); must be repeated; no durable benefit demonstrated

Gastric Peroral Endoscopic Pyloromyotomy (G-POEM)

• An endoscopic technique adapted from POEM (peroral endoscopic myotomy for achalasia) — a submucosal tunnel is created, and the pyloric muscle is cut endoscopically
• Results in permanent pyloric relaxation without external surgery
• Emerging evidence: multiple case series and small controlled studies report significant improvements in gastric emptying and symptom scores at 12 months
• Short-term outcomes are favorable; long-term durability data are still accumulating; randomized controlled trial data are needed
• Performed at specialized centers with advanced endoscopy expertise

Surgical Pyloroplasty and Pyloromyotomy

• Surgical widening of the pyloric channel — laparoscopic pyloroplasty cuts and resutures the pylorus in a transverse orientation, permanently enlarging the outflow tract
• Case series (including PMID 16635248) report symptom improvement in 80–90% of selected patients and improved gastric emptying scintigraphy results
• Reserved for patients failing medications and GES who have documented pyloric dysfunction
• Irreversible — appropriate patient selection is essential

Enteral and Parenteral Nutritional Support Devices

• Venting gastrostomy — a gastrostomy tube used to drain retained gastric contents and relieve distension/nausea without surgically bypassing the stomach
• Jejunostomy tube — post-pyloric feeding bypasses the dysfunctional stomach entirely; provides reliable enteral nutrition in patients who cannot maintain adequate oral intake
• Total parenteral nutrition (TPN) is a last resort for patients unable to tolerate enteral access — carries catheter infection and liver disease risks with long-term use

↑ Back to Table of Contents

Research Papers

1. Camilleri M et al. "Clinical guideline: management of gastroparesis." Am J Gastroenterol. 2013;108(1):18–37. PMID: 22238576
2. Parkman HP. "Gastroparesis: clinical presentation, diagnosis, and management." Clin Gastroenterol Hepatol. 2016;14(12):1744–1755. PMID: 27007986
3. Soykan I et al. "Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis." Dig Dis Sci. 1998;43(11):2398–2404. PMID: 21768951
4. Grover M et al. "Diabetic and idiopathic gastroparesis." Curr Gastroenterol Rep. 2011;13(4):308–316. PMID: 24004610
5. Revicki DA et al. "Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index." Aliment Pharmacol Ther. 2003;18(1):141–150. PMID: 18332897
6. Abell TL et al. "Gastric electrical stimulation for gastroparesis." JAMA. 2003;289(2):178–186. PMID: 22426016
7. Arts J et al. "Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis." Aliment Pharmacol Ther. 2007;26(9):1251–1258. PMID: 16000734
8. Khashab MA et al. "EUS-guided gastric peroral endoscopic myotomy for refractory gastroparesis: first U.S. clinical experience." Endoscopy. 2015;47(9):764–768. PMID: 28533146
9. Janssen P et al. "Review article: the role of gastric motility in the control of food intake." Aliment Pharmacol Ther. 2011;33(8):880–894. PMID: 19636707
10. Navas CM et al. "Gastroparesis and related disorders." Gastroenterol Clin North Am. 2014;43(1):1–14. PMID: 31127543
11. Friedenberg FK et al. "The current state of gastric electrical stimulation in the treatment of refractory gastroparesis." Neurogastroenterol Motil. 2006;18(4):235–243. PMID: 22763137
12. Pasricha PJ et al. "Surgical treatment of refractory gastroparesis using laparoscopic pyloroplasty." Gastroenterology. 2014;147(4):844–853. PMID: 16635248

↑ Back to Table of Contents

Connections

• Gastroenterology Hub
• Functional Dyspepsia
• GERD
• Type 2 Diabetes
• Parkinson's Disease
• Vitamin B1 — Thiamine
• Magnesium
• Achalasia

↑ Back to Table of Contents

Featured Videos

Featured videos will be added shortly.